

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 July 2019 (11.07.2019)



(10) International Publication Number
WO 2019/135259 A1

(51) International Patent Classification:

C07D 487/14 (2006.01) A61P 9/00 (2006.01)
A61K 31/522 (2006.01) A61P 29/00 (2006.01)
A61P 25/00 (2006.01) A61P 35/00 (2006.01)
A61P 11/00 (2006.01) A61P 37/00 (2006.01)
A61P 21/00 (2006.01)

(21) International Application Number:

PCT/IN2019/050009

(22) International Filing Date:

04 January 2019 (04.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201821000484 04 January 2018 (04.01.2018) IN

(71) Applicant: **IMPETIS BIOSCIENCES LTD.** [IN/IN];
Bombay House, First Floor, Homi Mody Street, Maharashtra,
Mumbai 400001 (IN).

(72) Inventors: **BASU, Sujay**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **THORAT, Sachin**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **SHEJUL, Yogesh**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **PAN-MAND, Anil**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **PATEL, Meena**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **KHOSE, Goraksha**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **BONAGIRI, Rajesh**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **BARAWKAR, Dinesh**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **KULKARNI, Bheemashankar**; C/o Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN). **MOOKHTIAR, Kasim**; C/o

Tata Industries Ltd Bombay House, First Floor, Homi Mody Street, Maharashtra, Mumbai 400001 (IN).

(74) Agent: **LAKSHMIKUMARAN, Malathi** et al.; B6/10, Safdarjung Enclave, New Delhi 110029 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).



Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with amended claims (Art. 19(1))

(54) Title: TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF



(I) (57) Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).